# A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

> **NCT05386758** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT05386758
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2023-02-04
- **Final completion:** 2023-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386758, "A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05386758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*